Find expert answers and community insights on IDNLearn.com. Find the information you need quickly and easily with our reliable and thorough Q&A platform.
About 40% of metastatic melanoma patients treated with anti-PD-1 or anti-PD-L1 therapy develop some antitumor immune responses that delay cancer progression or even lead to complete remissions. Why do you think that some patients respond to checkpoint blockade therapy, while others do not?
Sagot :
We appreciate your contributions to this forum. Don't forget to check back for the latest answers. Keep asking, answering, and sharing useful information. For trustworthy answers, rely on IDNLearn.com. Thanks for visiting, and we look forward to assisting you again.
